diabetes. typeII,Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: cinnamon powder cap 500 mg ,BD,for three months. Intervention 2: placebo,cap 500 mg, BD , for three months.
Treatment - Drugs
Placebo
cinnamon powder cap 500 mg ,BD,for three months
placebo,cap 500 mg, BD , for three months
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: informed consent to participate in the study; patients with type 2 diabetes; Patients who only use oral medications to control their blood sugar ;Lack of disease or complications of diabetes ; body mass index between 18.5 and 40 ; Patients with a fasting blood glucose between 126 to 250 milligrams per deciliter . Exclusion criteria: People who change during the study their treatment to insulin ; Lack of regular use of oral capsules (including cinnamon or placebo) ;sensitivity to other diseases during the study drug ; Cancel participate on the study; patients with a BMI of less than 18.5 (thin) and patients with a body mass index over 40 (morbid obese)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose. Timepoint: at onset and after 3 months. Method of measurement: blood sample.;Glycosylated Hemogolobine. Timepoint: at onset and after 3 months. Method of measurement: blood sample.;2hours post parandial glougose. Timepoint: at onset and after 3 months. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mezaj. Timepoint: onset. Method of measurement: questionary.;Body activity. Timepoint: onset. Method of measurement: questionary.;Calery intake. Timepoint: onset. Method of measurement: food frequency questionary.;Triglyceride. Timepoint: at onset and after 3 months. Method of measurement: blood sample.;Colstrol. Timepoint: at onset and after 3 months. Method of measurement: blood sample.;Weight. Timepoint: at onset and after 3 months. Method of measurement: digital scale (OMRON BF511).;Body mass indwx. Timepoint: at onset and after 3 months. Method of measurement: digital scale (OMRON BF511).;Fat mass percentage. Timepoint: at onset and after 3 months. Method of measurement: digital scale (OMRON BF511).;Muscle mass index. Timepoint: at onset and after 3 months. Method of measurement: digital scale (OMRON BF511).;Hdl. Timepoint: at onset and after 3 months. Method of measurement: blood sample.;Ldl. Timepoint: at onset and after 3 months. Method of measurement: blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoghayeh Zare
Shiraz Medical University
Outcome results
None listed